ATE411016T1 - Verfahren zur prophylaxis oder behandlung von östrogen-abhängigen krankheiten - Google Patents

Verfahren zur prophylaxis oder behandlung von östrogen-abhängigen krankheiten

Info

Publication number
ATE411016T1
ATE411016T1 AT98940886T AT98940886T ATE411016T1 AT E411016 T1 ATE411016 T1 AT E411016T1 AT 98940886 T AT98940886 T AT 98940886T AT 98940886 T AT98940886 T AT 98940886T AT E411016 T1 ATE411016 T1 AT E411016T1
Authority
AT
Austria
Prior art keywords
estrogen
treatment
prophylaxis
dependent diseases
dependent
Prior art date
Application number
AT98940886T
Other languages
English (en)
Inventor
Donald Mcdonnell
John Norris
Caroline Connor
Ashini Wijayaratne
Original Assignee
Univ Duke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Duke filed Critical Univ Duke
Application granted granted Critical
Publication of ATE411016T1 publication Critical patent/ATE411016T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT98940886T 1997-08-15 1998-08-14 Verfahren zur prophylaxis oder behandlung von östrogen-abhängigen krankheiten ATE411016T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5588197P 1997-08-15 1997-08-15

Publications (1)

Publication Number Publication Date
ATE411016T1 true ATE411016T1 (de) 2008-10-15

Family

ID=22000784

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98940886T ATE411016T1 (de) 1997-08-15 1998-08-14 Verfahren zur prophylaxis oder behandlung von östrogen-abhängigen krankheiten

Country Status (21)

Country Link
US (1) US7307102B2 (de)
EP (1) EP1019057B1 (de)
JP (1) JP2001515038A (de)
KR (1) KR20010022956A (de)
CN (1) CN1275911A (de)
AT (1) ATE411016T1 (de)
AU (1) AU757206B2 (de)
BR (1) BR9811946A (de)
CA (1) CA2301032C (de)
CZ (1) CZ300929B6 (de)
DE (1) DE69840126D1 (de)
EE (1) EE200000077A (de)
ES (1) ES2312189T3 (de)
HU (1) HUP0002852A3 (de)
IL (1) IL134445A0 (de)
NO (1) NO20000752D0 (de)
NZ (1) NZ502738A (de)
PL (1) PL338555A1 (de)
RU (1) RU2214236C2 (de)
UA (1) UA70925C2 (de)
WO (1) WO1999008682A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6413533B1 (en) * 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
JP2003520758A (ja) 1998-06-12 2003-07-08 リガンド・ファーマシューティカルズ・インコーポレイテッド 抗エストロゲン耐性乳癌のｒｘｒモジュレーターを用いた処置
GB9824207D0 (en) * 1998-11-04 1998-12-30 Zeneca Ltd Neurological disorders
DE60043305D1 (de) * 1999-07-06 2009-12-24 Endorech Inc Pharmazeutische zubereitungen zur behandlung von insulinresitenz
CO5271709A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos
US6528681B2 (en) * 2000-04-05 2003-03-04 Bristol-Meyers Squibb Pharma Company Halogenated triphenylethylene derivatives as selective estrogen receptor modulators
US6417394B2 (en) * 2000-04-05 2002-07-09 Bristol Myers Squibb Pharma Company Specific salt forms of triphenylethylene derivatives as selective estrogen receptor modulators
AU2001272249A1 (en) * 2000-07-05 2002-01-14 Andrew J. E. Seely Method and apparatus for multiple patient parameter variability analysis and display
ATE415161T1 (de) * 2001-02-15 2008-12-15 Janssen Pharmaceutica Nv Farnesyl-protein-transferase hemmer in kombination mit antiöstrogenen
US20020164581A1 (en) * 2001-03-12 2002-11-07 Chawnshang Chang Methods for identifying compounds that do not attenuate the protective effects of estrogen
WO2003016270A2 (en) 2001-08-11 2003-02-27 Bristol-Myers Squibb Pharma Company Selective estrogen receptor modulators
BRPI0413013A (pt) * 2003-07-28 2006-10-03 Smithkline Beecham Corp composto, seus sais, solvatos, e derivados farmaceuticamente funcionais, composição farmacêutica, uso de um composto, e, métodos para o tratamento ou profilaxia de condições ou distúrbios, e de doenças
WO2006007314A1 (en) 2004-06-23 2006-01-19 Sirion Therapeutics, Inc. Methods and compositions for treating ophthalmic conditions with retinyl derivatives
AU2005304822B2 (en) 2004-11-04 2008-10-16 Sirion Therapeutics, Inc. Modulators of retinol-retinol binding protein (RBP)-transthyretin (TTR) complex formation
SG144145A1 (en) * 2004-12-08 2008-07-29 Sirion Therapeutics Inc Methods, assays and compositions for treating retinol-related diseases
US20060264413A1 (en) * 2005-04-18 2006-11-23 Sri International Method and composition for inhibiting cell proliferation and angiogenesis
UA81382C2 (en) * 2005-07-11 2007-12-25 Composition for treating retinol-related diseases by modulation of retinol binding
JP2010540127A (ja) * 2007-10-03 2010-12-24 オタワ ヘルス リサーチ インスティチュート １つ以上の臓器の経時的生理的パラメータ変動を監視するための方法および装置
WO2009151683A2 (en) 2008-03-12 2009-12-17 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
AU2009313927A1 (en) 2008-11-13 2010-05-20 Astrazeneca Ab Azaquinolinone derivatives and uses thereof
JP2013528223A (ja) 2010-06-10 2013-07-08 アラゴン ファーマシューティカルズ，インク． エストロゲン受容体モジュレーターおよびその用途
US8853423B2 (en) 2010-06-17 2014-10-07 Seragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
GB2483736B (en) 2010-09-16 2012-08-29 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
US9193714B2 (en) 2011-12-14 2015-11-24 Seragon Pharmaceuticals, Inc. Fluorinated estrogen receptor modulators and uses thereof
CN102532073A (zh) * 2011-12-30 2012-07-04 北京赛林泰医药技术有限公司 作为选择性雌激素受体调节剂的乙烯衍生物
CN102584687A (zh) * 2011-12-30 2012-07-18 北京赛林泰医药技术有限公司 作为选择性雌激素受体调节剂的乙烯衍生物
NZ630124A (en) 2012-03-20 2016-01-29 Seragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
WO2017100715A1 (en) * 2015-12-09 2017-06-15 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective estrogen receptor downregulator compounds
CN111094227A (zh) * 2017-07-28 2020-05-01 里科瑞尔姆Ip控股有限责任公司 丙烯酸类似物

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE637389A (de) 1962-09-13
GB1029221A (en) 1963-09-02 1966-05-11 Ici Ltd Triarylalkane derivatives
GB1079747A (en) 1965-07-07 1967-08-16 Ici Ltd Alkene derivatives
US3637856A (en) 1965-07-12 1972-01-25 Ici Ltd Trans-1-p-(dialkylaminoalkyl) phenyl-1 2-diphenyl-alk-1-enes and salts thereof
GB1128379A (en) 1966-06-20 1968-09-25 Ici Ltd Novel alkene derivatives, process for the preparation thereof and compositions containing the same
GB1560274A (en) 1977-02-28 1980-02-06 Ici Ltd Phenylbut 1-ene derivatives having antiostrogenicactivity
DE2860900D1 (en) 1977-08-22 1981-11-05 Ici Plc Triphenylalkene derivatives, process for their preparation and pharmaceutical compositions containing them
US4206234A (en) 1977-08-22 1980-06-03 Imperial Chemical Industries Limited Triphenylbut-1-ene derivatives and pharmaceutical compositions and uses thereof
EP0019377B1 (de) 1979-05-15 1982-08-04 Imperial Chemical Industries Plc 1-Hydrocarbyloxyphenyl-1.2-diphenylalken-Derivate, ihre Herstellung und sie enthaltende pharmazeutische Zusammensetzung
HU178253B (en) 1979-08-15 1982-04-28 Gyogyszerkutato Intezet Process for preparing 1,1,2-triphenyl-propane and -propane derivatives
DE3046719C2 (de) 1980-12-11 1983-02-17 Klinge Pharma GmbH, 8000 München 1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel
FI77839C (fi) 1982-05-27 1989-05-10 Farmos Oy Foerfarande foer framstaellning av nya terapeutiskt effektiva trifenylalkan- och alkenderivat.
US5491173A (en) * 1982-06-25 1996-02-13 Orion-Yhtyma Oy Tri-phenyl alkene derivatives and their preparation and use
CA1229604A (en) 1984-02-14 1987-11-24 Lorne J. Brandes Aminoalkyl ethers of phenols as antiproliferative anticancer agents
US4760053A (en) 1984-08-02 1988-07-26 Fernand Labrie Combination therapy for selected sex steroid dependent cancers
US4729999A (en) 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency
GB8604528D0 (en) 1986-02-24 1986-04-03 Ici Plc Therapeutic agents
US4859695A (en) 1986-06-10 1989-08-22 Merck & Co., Inc. Antiestrogen agents having anabolic activity in animals
CA1289570C (en) 1986-06-16 1991-09-24 Tetsuji Asao 1,1,2-triaryl-1-alkene derivatives
GB2210875B (en) * 1987-10-09 1991-05-29 Farmos Oy Aromatase inhibiting 4(5)-imidazoles
DE3736682A1 (de) 1987-10-29 1989-05-11 Klinge Co Chem Pharm Fab Verfahren zur herstellung von trans-1,1,2-triphenyl-but-1-en-derivaten
US5393785A (en) * 1988-10-31 1995-02-28 Endorecherche, Inc. Therapeutic antiestrogens
US5119827A (en) 1990-09-05 1992-06-09 Board Of Regents, The University Of Texas System Mechanisms of antiestrogen resistance in breast cancer
US5189212A (en) * 1990-09-07 1993-02-23 University Of Georgia Research Foundation, Inc. Triarylethylene carboxylic acids with estrogenic activity
CA2092996A1 (en) 1990-10-01 1992-04-02 David Yang High affinity tamoxifen derivatives and uses thereof
WO1992019585A1 (en) 1991-04-30 1992-11-12 Asahi Kasei Kogyo Kabushiki Kaisha Triphenylethylene derivative and pharmaceutical preparation containing the same
DK0660821T3 (da) * 1992-09-15 1998-09-21 Merrell Pharma Inc Ikke-metaboliserbare clomiphen-analoge til behandling af tamoxifen-resistente tumorer
DE4311870C2 (de) * 1993-04-10 1998-07-30 Altramed Holdings Ltd Verwendung eines Anti-Östrigens zur Therapie und Prophylaxe von Demenz-Erkrankungen
US5681835A (en) * 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5455275A (en) * 1994-05-11 1995-10-03 Eli Lilly And Company Methods for inhibiting endometriosis and uterine fibroid disease with 1,1,2-triphenylbut-1-ene derivatives

Also Published As

Publication number Publication date
UA70925C2 (uk) 2004-11-15
CN1275911A (zh) 2000-12-06
AU8906398A (en) 1999-03-08
EP1019057A1 (de) 2000-07-19
US7307102B2 (en) 2007-12-11
AU757206B2 (en) 2003-02-06
JP2001515038A (ja) 2001-09-18
RU2214236C2 (ru) 2003-10-20
CZ300929B6 (cs) 2009-09-16
WO1999008682A1 (en) 1999-02-25
CA2301032C (en) 2009-01-13
PL338555A1 (en) 2000-11-06
NZ502738A (en) 2002-06-28
NO20000752L (no) 2000-02-15
CZ2000531A3 (en) 2001-05-16
DE69840126D1 (de) 2008-11-27
BR9811946A (pt) 2000-08-22
HUP0002852A2 (hu) 2001-10-28
NO20000752D0 (no) 2000-02-15
US20030232795A1 (en) 2003-12-18
KR20010022956A (ko) 2001-03-26
IL134445A0 (en) 2001-04-30
EP1019057A4 (de) 2006-06-14
CA2301032A1 (en) 1999-02-25
EP1019057B1 (de) 2008-10-15
EE200000077A (et) 2000-12-15
ES2312189T3 (es) 2009-02-16
HUP0002852A3 (en) 2001-11-28

Similar Documents

Publication Publication Date Title
ATE411016T1 (de) Verfahren zur prophylaxis oder behandlung von östrogen-abhängigen krankheiten
DE69826695D1 (de) Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen
ATE241358T1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
ATE279181T1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
DE69931377D1 (de) Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren
ATE415962T1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
ATE300292T1 (de) Thyroxin-analoge mit keiner signifikanten hormonellen aktivität zur behandlung von bösartigen tumoren
ATE258796T1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
ATE362374T1 (de) Verfahren und zusammensetzungen zur prevention oder behandlung von krebs und von krebs assoziertem knochenverlust
ATE198706T1 (de) Polyamin-verbindungen zur behandlung von proliferativer erkrankungen
ZA200004260B (en) Treatment of skin disorders.
ATE222119T1 (de) Verwendung von erythropoietin zur behandlung von multiple myelom
ATE271873T1 (de) Verwendung von glukosamin und glukosaminderivaten zur schnellen linderung von juckreiz oder lokalisiertem schmerz
ATE196083T1 (de) Verwendung von ferrioxamin-b zur behandlung septischen schocks
ATE239467T1 (de) Methode zur behandlung oder verhütung von interstitieller blasenentzundung
ATE251462T1 (de) Verfahren zur behandlung von narbengewebe
ATE261724T1 (de) Antikonvulsive derivate zur behandlung von posttraumatischen stresserkrankungen
DE60144493D1 (de) Verfahren zur bestimmung und behandlung von tuberöse-sklerose komplex assoziierten erkrankungen
EP1056458A4 (de) Methoden zur behandlung von schmerzen, einscliesslich chronischen und frauenspezifischen schmerzen
ATE206052T1 (de) Verwendung von sphingosin-1-phosphat, sphingosin- 1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten
ATE360425T1 (de) Verwendung von quetiapin für die behandlung von kokain-abhängigkeit
ATE369143T1 (de) Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen
ATE302009T1 (de) Ubichinon qn zur behandlung von migräneschmerzen
ATE291434T1 (de) Verwendung von angiotensin zur behandlung von krebsmetastasierung
DE60334289D1 (de) Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties